Thom K, Male Christoph, Falger J, Pabinger I
Children's Hospital, Medical University of Vienna, 1090 Vienna, Austria.
Hamostaseologie. 2009 May;29(2):149-50.
The most serious complication of haemophilia A is development of a high-titre factor VIII (FVIII) inhibitor which renders the patient unresponsive to FVIII replacement. Bleeding complications can only be controlled using FVIII-inhibitor bypassing agents but their effect is less certain. The ultimate goal is to eliminate the inhibitor by immune tolerance induction therapy (ITI) using daily high doses of FVIII. The success rate of ITI using various protocols is between 56 and 79% (1, 2). If ITI is unsuccessful, the inhibitor usually persists throughout life. We report on a patient with a high titre FVIII inhibitor that persisted after ITI but spontaneously disappeared 15 years later.
甲型血友病最严重的并发症是产生高滴度的凝血因子VIII(FVIII)抑制物,这会使患者对FVIII替代治疗无反应。出血并发症只能使用FVIII抑制物旁路制剂来控制,但效果不太确切。最终目标是通过每日大剂量使用FVIII的免疫耐受诱导疗法(ITI)来消除抑制物。采用各种方案进行ITI的成功率在56%至79%之间(1, 2)。如果ITI不成功,抑制物通常会终生存在。我们报告了一名患者,其FVIII抑制物滴度较高,在ITI后持续存在,但15年后自发消失。